Nxera Pharma Co., Ltd.

In individual announcements released on the 26th, ABEJA resolved to establish a wholly-owned subsidiary in Singapore. Globing plans a significant profit increase and higher dividend for the fiscal year ending May 2027 (IFRS). Susmed's exclusive sales contract with Shionogi for its insomnia disorder app has ended. Nexera received a milestone payment of approximately 1.591 billion yen related to its partner Neurocrine's Phase 2 trial for cognitive impairment in Alzheimer's disease. Kasumigaseki Capital sold a property held for sale (Miami development land) for its first U.S. project, and Yamaha announced the partial sale of its shares in Yamaha Motor. Matsui Securities set its interim dividend for the fiscal year ending March 2027 at 28 yen (compared to 25 yen in the same period last year), and Medical Net resolved the material weakness in internal control over financial reporting that had been disclosed.

Nxera Pharma reported a net profit of JPY 1,591 million (US$10.1 million) for the six months ended 30 June 2026, reversing a net loss of JPY 3,137 million (US$21.1 million) in the prior corresponding period. Revenue totalled JPY 18,910 million (US$119.6 million), an increase of JPY 3,815 million (US$18.0 million) versus the prior corresponding period, driven by eight R&D milestone events in the current quarter compared with five a year earlier. Operating profit reached JPY 1,881 million (US$11.9 million) against an operating loss of JPY 2,756 million (US$18.5 million), while core operating profit surged to JPY 6,494 million (US$41.1 million) from JPY 364 million (US$2.5 million). The company highlighted progress across partnered programs, including milestone payments from Neurocrine Biosciences, AbbVie, and Centessa Pharmaceuticals, and noted that Lilly's acquisition of Centessa does not affect Nxera's rights to future milestone and royalty payments from the jointly created orexin receptor agonist pipeline.

Nxera Pharma has reached a fourth R&D milestone under its multi-target neurological disease collaboration with AbbVie, triggering a US$10 million payment. This milestone, the second achieved in 2026, relates to identifying validated hit molecules against a neurology target. Since the collaboration began in 2022, Nxera has received US$40 million in total milestone payments from AbbVie. Under the agreement, Nxera is eligible for up to US$1.2 billion in further option, development and commercial milestones, plus tiered royalties on sales.